Interactions between human immunodeficiency and hepatitis C viruses;Interactions entre les virus de l'immunodeficience humaine et de l'hepatite C

Revue de Medecine Interne

Volumn 19, Issue 12, 1998, Pages 885-891

  Pol, S ^a   Zylberberg, H ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Hepatitis C virus; Human immune deficiency virus; Interferon

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

DISEASE ASSOCIATION; EARLY DIAGNOSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; REVIEW; VIREMIA; VIRUS REPLICATION;

EID: 0032299884     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(99)80061-7     Document Type: Article

References (48)

1. 1 Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996 ; 23 : 1117-25
2. 2 Conférence de consensus. Hépatite C : dépistage et traitement. Gastroentérol Clin Biol 1997 ; 20 (suppl) : 1-216
3. 3 NIH Consensus Development Conference. Management of hepatitis C. Hepatology 1997 ; 26 (suppl) : 1-156
4. 4 Serfaty L, Noubaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity and risk factors of liver disease in blood donnors positive in a second generation anti-hepatitis virus screening test. Hepatology 1995 ; 2 : 725-9
5. 5 Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C et al. Transmission of hepatitis C virus from mother to infants. N Engl J Med 1994 ; 330 : 744-50
6. 6 Dubois F, Désenclos JC, Mariotte N, Goudeau A and the Collaborative Study Group. Hepatitis C in French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997 ; 25 : 1490-6
7. 7 Colombo M. Hepatocellular carcinoma. J Hepatol 1992 ; 15 : 225-36
8. 8 Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 ; 349 : 825-32
9. 9 Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997 ; 26 : 485-90
10. 10 Fontaine H, Pol S, Carnot F, Zylberberg H, Berthelot P, Bréchot C et al. Predictive factors for HCV-related cirrhosis: comparison between immunocompetent and immunocompromised patients. J Hepatol 1998 ; 29 : 12-9
11. 11 Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C and the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995 ; 122 : 161-8
12. 12 Lifson AR, Hessol NA, Rutherford GW. Progression and clinical outcome of infection due to human immunodeficiency virus. Clin Infect Dis 1992 ; 14 : 966-72
13. 13 Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993 ; 17 : 117-9
14. 14 Llibre JM, Garcia E, Aloy A, Valls J. Hepatitis C virus infection and progression of infection due to human immunodeficiency virus. Clin Infect Dis 1993 ; 16 : 182
15. 15 Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991 ; 163 : 414-5
16. 16 Giovanninni M, Tagger A, Ribero ML, Zuccotti G, Pogliani L, Grossi A et al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990 ; 335 : 1166
17. 17 Ercilla MG, Fortuny C, Roca A, Gil MP, Espuny R, Celis R et al. HCV vertical transmission. A prospective study. In: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease (The 8th Triennal Congress) Tokyo, 1993
18. 18 Eyster ME, Alter HU, Aledort LM, Quan SM, Halzakis A, Goedert JJ. Heterosexual cotransmission of hepatitis C virus and human immunodeficiency virus. Ann Intern Med 1991 ; 115 : 764-8
19. 19 Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995 ; 9 : 1131-6
20. 20 Marcellin P, Martinet-Peignou M, Elias A, Branger M, Courtois F, Level R et al. Hepatitis C virus (HCV) viremia in Human Immunodeficiency Virus-seronegative and seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994 ; 170 : 433-5
21. 21 Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990 ; 4 : 1275-7
22. 22 Tuveri R, Rothschild C, Pol S, Reijasse D, Persico T, Gazengel C et al. Hepatitis C virus genotypes in french haemophiliacs: kinetics and reappraisal of mixed infections. J Med Virol 1997 ; 51 : 36-41
23. 23 Gerber MA. Pathobiologic effects of hepatitis C. J Hepatol 1995 ; 22 : 83-6
24. 24 Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997 ; 158 : 1473-81
25. 25 Vento S, Cainelli F, Mirandola F, Cosco L, Perri GDI, Solbiati M et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996 ; 347 : 92-3
26. 26 Ballardini G, Groff P, Pontisso P, Giostra F, Fransesconi R, Lenzi M et al. Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatement in patients with chronic hepatitis C. J Clin Invest 1995 ; 95 : 2067-75
27. 27 Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989 ; 97 : 1559-61
28. 28 Eyster ME, Diamondstone LS, Lien JM. Natural history of hepatitis C virus infection in multitransfused effect of coinfection with human immunodeficiency virus. The multicenter hemophilia cohort study. J Acquired Immune Defic Syndr 1993 ; 6 : 602-10
29. 29 Soto B, Rodrigo L, Del-Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Lissen E. Influence of human immunodeficiency virus type 1 infection on the natural history of chronic parenteral-acquired hepatitis C. A multicenter study on 547 patients [Abstract]. J Hepatol 1994 ; 21 (suppl) : 25
30. 30 Andreu J, Sanchez-Quijano A, Gavilan F, Luque F, Abad MA, Soto B et al. Influence of human immunodeficiency virus type 1 infection on the natural history of chronic parenteral-acquired hepatitis C [Abstract]. J Hepatol 1994 ; 21 (suppl) : 95
31. 31 Ridzon R, Gallagher K, Ciesielski C, Mast EE, Ginsberg MB, Robertson BJ et al. Simultaneous transmission of Human Immunodeficiency Virus and Hepatitis C Virus from a needle-stick injury. N Engl J Med 1997 ; 336 : 919-22
32. 32 Pol S, Lamorthe B, Trinh Thi N, Thiers V, Carnot F, Zylberberg H et al. Retrospective analysis of the impact of HIV infection and alcohol abuse in a large cohort of drug users. J Hepatol 1998 ; 28 : 945-50
33. 33 Geffray L, Rosenthal E, Perronne C, Cacoub P, Raguin G, Veyssier P et al. et les membres du GERMIVIC, de la SNFMI et du RESIF [Abstract]. Mortalité par cirrhose virale C en 1995 dans une file active de 14 487 patients infectés par le VIH (étude rétrospective multicentrique du groupe GERMIVIC). Rev Méd Interne 1997 ; 18 (suppl) : 78
34. 34 Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM et al. for the UK Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilia men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997 ; 350 : 1425-31
35. 35 Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer H, Perrillo RP et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989 ; 321 : 1501-6
36. 36 Roméo R, Pol S, Berthelot P, Bréchot C. Eradication of HCV RNA after alpha-interferon therapy. Ann Intern Med 1994 ; 58 : 315-6
37. 37 Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997 ; 127 : 875-81
38. 38 Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, Benhamou JP. Recombinant interferon alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992 ; 165 : 723-6
39. 39 Marriott E. Navas S, Del Romero J, Garcia S, Castillo I, Quiroga JA et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993 ; 40 : 107-11
40. 40 Soriano V, Garcia-Samaniego J, Bravo R. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. J Infection 1995 ; 31 : 9-13
41. 41 Lipsky James J. Antiretroviral drugs for AIDS. Lancet 1996 ; 348 : 800-3
42. 42 Braü N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated by indinavir. Lancet 1997 349 : 924-5
43. 43 Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2', 3'-dideoxyinosine (ddI). Ann Intern Med 1991 ; 115: 283-4
44. 44 Carr A, Emery S, Kelleher A, Law M, Cooper DA. CD8+ Lymphocyte responses to antiretroviral therapy of HIV infection. J AIDS Hum Retrovirol 1996 ; 13 : 320-6
45. 45 Zylberberg H, Carnot F, Mamzer MF, Blancho G, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997 ; 63 : 158-60
46. 46 Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996 ; 111 : 1307-12
47. 47 Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995 ; 23 : 8-12
48. 48 Reichard O, Norkrans G, Frydén A, Braconier JH, Sönneborg A, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998 ; 351 : 83-7